CAMKK2, Regulated by Promoter Methylation, is a Prognostic Marker in Diffuse Gliomas

受启动子甲基化调控的 CAMKK2 是弥漫性胶质瘤的预后标志物

阅读:8
作者:Da-Ming Liu, Hong-Jun Wang, Bo Han, Xiang-Qi Meng, Ming-Hui Chen, Dong-Bo Yang, Ying Sun, Yong-Li Li, Chuan-Lu Jiang

Aims

To explore the expression, methylation pattern, the prognostic value, and the biological consequences of CAMKK2 in gliomas.

Conclusions

The expression level of CAMKK2 could be regulated by promoter methylation. CAMKK2 serves as a prognostic marker in gliomas and could be a potential therapeutic target in gliomas.

Methods

The expression and methylation pattern of CAMKK2 was inferred and validated from mRNA expression profile (N = 866) and methylation profile (N = 426) of glioma tissue samples, and independent samples were used for further validation by IHC and pyrosequencing. To explore the function of CAMKK2 in gliomas, in vitro studies, colony formation assays and migration and invasion assays were performed.

Results

We found the upregulation of CAMKK2 in high-grade glioma samples was associated with promoter hypomethylation. An elevated expression of CAMKK2 was associated with worse prognosis. By in vitro assays, we demonstrated that CAMKK2 could promote cell migration, invasion, and proliferation. Conclusions: The expression level of CAMKK2 could be regulated by promoter methylation. CAMKK2 serves as a prognostic marker in gliomas and could be a potential therapeutic target in gliomas.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。